Crossject

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 12:35:56 01/07/2024 pm IST			5-day change	1st Jan Change
1.59 ^EUR	-2.21%		-5.92%	-68.01%

13/06	Crossject SA Announces the Appointment of Dan Chiche as Chief Medical Officer North America	CI
05/06	Crossject: successful capital increase	CF

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Crossject

Crossject SA Announces the Appointment of Dan Chiche as Chief Medical Officer North America	13/06	CI
Crossject: successful capital increase	05/06	CF
CROSSJECT : Success of the capital increase	05/06	AL
Crossject Raises EUR8 Million via Rights Offering	05/06	MT
Crossject Société Anonyme announced that it has received ?7.999999 million in funding	04/06	CI
Crossject: capital increase until May 30	27/05	CF
Crossject: praised for extended agreement on Zepizure	03/05	CF
Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe	02/05	CI
CROSSJECT : We welcome the securing of the group’s financial needs	02/05	AL
CROSSJECT : Patience is a virtue… hopefully	03/04	AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
CROSSJECT : Invest Securities slightly reduces its target	28/02	CF
CROSSJECT : Securing the financing needs	28/02	AL
Crossject: share price falls after convertible bond issue	27/02	CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding	26/02	CI
CROSSJECT : No news is not always good news...	08/02	AL
Crossject: strategy advances, but visibility worries	07/02	CF
CROSSJECT : Marketing initiative in the US	06/01	AL
Crossject: Syneos Health hired for Zepizure in the USA	05/01	CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment	05/01	MT
CROSSJECT : A new distribution agreement in Northern Europe	03/01	AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU	22/12	MT
Crossject: commercial agreement in Northern Europe	22/12	CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe	22/12	CI
CROSSJECT : H1 23: no surprises before the release of the detailed accounts in October	28/23/28	AL

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Sector

Medical Equipment, Supplies & Distribution

More about the company